chlorambucil: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
chlorambucil: clinical details
Prescribing considerations
- Restrict use to clinicians experienced with cytotoxic therapy.
- Assess marrow reserve and recent chemotherapy or radiotherapy exposure before treatment.
- Balance potential benefit against cumulative risks of irreversible myelosuppression, mutagenicity, infertility and secondary haematological malignancy.
- Avoid prolonged exposure in patients who may undergo autologous stem-cell transplantation.
- Review pregnancy potential, contraception and fertility preservation before treatment where relevant.
- Monitor closely in hepatic impairment; reduced clearance may increase toxicity.
- Renal impairment with azotaemia may increase susceptibility to myelosuppression.
- Patients with nephrotic syndrome or a seizure history may have increased seizure risk.
Contraindications and cautions
- Hypersensitivity to chlorambucil or any tablet excipient.
- The lactose-containing product should not be used in specified rare hereditary disorders of galactose metabolism or absorption.
Monitoring
- Full blood count closely throughout treatment, recognising that neutrophil decline may continue after chlorambucil is stopped.
- Clinical assessment for infection, bleeding, anaemia and marrow failure.
- Liver function and toxicity in hepatic impairment; consider renal and hepatic function particularly in older people.
- New rash or mucosal lesions, seizures or neurological symptoms, and new respiratory symptoms.
- Long-term surveillance appropriate to the risk of secondary haematological malignancy.
Clinical pharmacology
Chlorambucil is an aromatic nitrogen-mustard bifunctional alkylating agent. It interferes with DNA replication and promotes apoptosis; its active major metabolite is phenylacetic acid mustard. Absorption is reduced by food, and metabolism is predominantly hepatic.
Formulation and product differences
- The selected product is a brown, film-coated tablet containing lactose.
- The tablets must remain intact and must not be divided, crushed or chewed.
- Store refrigerated in the original amber-glass bottle with child-resistant closure.
chlorambucil preparations and strengths
Tablet
Route: Oral
Strengths: 2 mg
chlorambucil interactions
The specialist team should review all prescribed, non-prescription and complementary products. Important examples include:
Live vaccines
Avoid during chlorambucil-related immunosuppression because the vaccine organism may cause infection.
Fludarabine, pentostatin or cladribine
These purine nucleoside analogues increased chlorambucil cytotoxicity in laboratory testing, although the clinical significance is uncertain.
Recent radiotherapy or other cytotoxic chemotherapy
Overlapping bone-marrow toxicity may be increased, so treatment timing and blood counts require specialist assessment.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.